Journal of Gastric Cancer

  • 제20권3호
  • /
  • Pages.328-336
  • /
  • 2020
  • /
  • 2093-582X(pISSN)
  • /
  • 2093-5641(eISSN)
대한위암학회 (The Korean Gastric Cancer Association)
권호 표지
DOI QR코드

DOI QR Code

Prognostic Factors in Stage IB Gastric Cancer after Surgical Resection

  • Yu, Byunghyuk (Gastric Cancer Center, Kyungpook National University Chilgok Hospital) ;
  • Park, Ji Yeon (Gastric Cancer Center, Kyungpook National University Chilgok Hospital) ;
  • Park, Ki Bum (Gastric Cancer Center, Kyungpook National University Chilgok Hospital) ;
  • Kwon, Oh Kyoung (Gastric Cancer Center, Kyungpook National University Chilgok Hospital) ;
  • Lee, Seung Soo (Department of Surgery, School of Medicine, Kyungpook National University) ;
  • Chung, Ho Young (Department of Surgery, School of Medicine, Kyungpook National University)
  • 투고 : 2020.05.14
  • 심사 : 2020.09.08
  • 발행 : 2020.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: The standard treatment for stage IB gastric cancer is curative surgery alone, but some patients show poor survival with disease recurrence after curative surgery. The aim of this study was to identify prognostic factors of recurrence and long-term survival in patients with stage IB gastric cancer after surgery. Materials and Methods: We retrospectively reviewed data from 253 patients with stage IB gastric cancer who underwent gastrectomy between 2011 and 2016 at Kyungpook National University Chilgok Hospital and analyzed the clinicopathological characteristics associated with recurrence and survival. Results: Fourteen patients experienced recurrence with a mean follow-up of 54.1 months. Two of these patients had locoregional recurrence and 12 patients had systemic recurrence. The median interval between the operation day and the day of recurrence was 11 months (range 4-56 months). Multivariate analysis revealed that lymphatic vessel invasion (LVI) (hazard ratio [HR], 3.851; 95% confidence interval [CI], 1.264-11.732) and the elderly (age≥65) (HR, 3.850; 95% CI, 1.157-12.809) were independent risk factors for recurrence after surgery. The LVI (HR, 3.630; 95% CI, 1.105-11.923) was the independent prognostic factors for disease-specific survival (DSS). The 5-year DSS rates were 96.8% in patients who did not have LVI, and 89.3% in patients who had LVI. Conclusions: This study shows that LVI was associated with recurrence and poor survival in patients with stage IB gastric cancer after curative gastrectomy. Patients diagnosed with LVI require careful attention for systemic recurrence during the follow-up period.

키워드

참고문헌

  1. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev 2014;23:700-713. https://doi.org/10.1158/1055-9965.EPI-13-1057
  2. Information Committee of Korean Gastric Cancer Association. Korean Gastric Cancer Association Nationwide Survey on Gastric Cancer in 2014. J Gastric Cancer 2016;16:131-140. https://doi.org/10.5230/jgc.2016.16.3.131
  3. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017;20:1-19. https://doi.org/10.1007/s10120-016-0622-4
  4. Guideline Committee of the Korean Gastric Cancer AssociationDevelopment Working Group & Review Panel. Korean practice guideline for gastric cancer 2018: an evidence-based, multi-disciplinary approach. J Gastric Cancer 2019;19:1-48. https://doi.org/10.5230/jgc.2019.19.e8
  5. Kwon OK, Kim SW, Chae HD, Ryu SW, Chung HY, Kim SW, et al. Validation of the 7th AJCC/UICC staging system for gastric cancer and a proposal for a new TNM system based on a prognostic score: a retrospective multicenter study. Ann Surg Treat Res 2016;91:295-302. https://doi.org/10.4174/astr.2016.91.6.295
  6. Edge SB, Byrd DR, Campton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York (NY): Springer-Verlag, 2010.
  7. Yokoyama T, Kamada K, Tsurui Y, Kashizuka H, Okano E, Ogawa S, et al. Clinicopathological analysis for recurrence of stage Ib gastric cancer (according to the second English edition of the Japanese classification of gastric carcinoma). Gastric Cancer 2011;14:372-7. https://doi.org/10.1007/s10120-011-0051-3
  8. Araki I, Hosoda K, Yamashita K, Katada N, Sakuramoto S, Moriya H, et al. Prognostic impact of venous invasion in stage IB node-negative gastric cancer. Gastric Cancer 2015;18:297-305. https://doi.org/10.1007/s10120-014-0362-2
  9. Toyokawa T, Ohira M, Sakurai K, Kubo N, Tanaka H, Muguruma K, et al. The role of adjuvant chemotherapy for patients with stage IB gastric cancer. Anticancer Res 2015;35:4091-4097.
  10. Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol 2010;17:3077-9. https://doi.org/10.1245/s10434-010-1362-z
  11. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. AJCC Cancer Staging Manual. 6th ed. New York (NY): Springer-Verlag, 2002.
  12. Amin MB, Edge SB, Greene FL, Schilsky RL, Gaspar LE, Washington MK, et al. AJCC Cancer Staging Manual. 8th ed. New York (NY): Springer, 2017.
  13. Aoyama T, Yoshikawa T, Fujikawa H, Hayashi T, Ogata T, Cho H, et al. Prognostic factors in stage IB gastric cancer. World J Gastroenterol 2014;20:6580-6585. https://doi.org/10.3748/wjg.v20.i21.6580
  14. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820. https://doi.org/10.1056/NEJMoa072252
  15. Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:1389-1396. https://doi.org/10.1016/S1470-2045(14)70473-5
  16. Kim JW, Hwang I, Kim MJ, Jang SJ. Clinicopathological characteristics and predictive markers of early gastric cancer with recurrence. J Korean Med Sci 2009;24:1158-1164. https://doi.org/10.3346/jkms.2009.24.6.1158
  17. Moriguchi S, Maehara Y, Korenaga D, Sugimachi K, Nose Y. Risk factors which predict pattern of recurrence after curative surgery for patients with advanced gastric cancer. Surg Oncol 1992;1:341-346. https://doi.org/10.1016/0960-7404(92)90034-I
  18. Kim H, Kim JH, Park JC, Lee YC, Noh SH, Kim H. Lymphovascular invasion is an important predictor of lymph node metastasis in endoscopically resected early gastric cancers. Oncol Rep 2011;25:1589-1595.
  19. Lee IS, Kang HJ, Park YS, Ryu MH, Yook JH, Kang YK, et al. Prognostic impact of extranodal extension in stage 1B gastric carcinomas. Surg Oncol 2018;27:299-305. https://doi.org/10.1016/j.suronc.2018.05.014
  20. Park JH, Ryu MH, Kim HJ, Ryoo BY, Yoo C, Park I, et al. Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancer. Gastric Cancer 2016;19:226-33. https://doi.org/10.1007/s10120-015-0464-5
  21. Wang S, Chen X, Fan J, Lu L. Prognostic significance of lymphovascular invasion for thoracic esophageal squamous cell carcinoma. Ann Surg Oncol 2016;23:4101-4109. https://doi.org/10.1245/s10434-016-5416-8
  22. Sung SY, Kwak YK, Lee SW, Jo IY, Park JK, Kim KS, et al. Lymphovascular invasion increases the risk of nodal and distant recurrence in node-negative stage I-IIA non-small-cell lung cancer. Oncology 2018;95:156-162. https://doi.org/10.1159/000488859
  23. Yuan H, Dong Q, Zheng B, Hu X, Xu JB, Tu S. Lymphovascular invasion is a high risk factor for stage I/II colorectal cancer: a systematic review and meta-analysis. Oncotarget 2017;8:46565-46579. https://doi.org/10.18632/oncotarget.15425
  24. Lu J, Dai Y, Xie JW, Wang JB, Lin JX, Chen QY, et al. Combination of lymphovascular invasion and the AJCC TNM staging system improves prediction of prognosis in N0 stage gastric cancer: results from a high-volume institution. BMC Cancer 2019;19:216. https://doi.org/10.1186/s12885-019-5416-8
  25. Li P, He HQ, Zhu CM, Ling YH, Hu WM, Zhang XK, et al. The prognostic significance of lymphovascular invasion in patients with resectable gastric cancer: a large retrospective study from Southern China. BMC Cancer 2015;15:370. https://doi.org/10.1186/s12885-015-1370-2
  26. Hwang JE, Hong JY, Kim JE, Shim HJ, Bae WK, Hwang EC, et al. Prognostic significance of the concomitant existence of lymphovascular and perineural invasion in locally advanced gastric cancer patients who underwent curative gastrectomy and adjuvant chemotherapy. Jpn J Clin Oncol 2015;45:541-546.
  27. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29:4387-4393. https://doi.org/10.1200/JCO.2011.36.5908
  28. Kunisaki C, Makino H, Kimura J, Takagawa R, Kosaka T, Ono HA, et al. Impact of lymphovascular invasion in patients with stage I gastric cancer. Surgery 2010;147:204-211. https://doi.org/10.1016/j.surg.2009.08.012

피인용 문헌

  1. Lymphangiosis carcinomatosa independently affects long-term survival of Non-Small Cell Lung Cancer patients vol.37, 2020, https://doi.org/10.1016/j.suronc.2021.101611